Metabolism of the novel dihydropyridine calcium channel blockers mebudipine and dibudipine by isolated rat hepatocytes

S. Bohlooli, M. Mahmoudian, G.G. Skellern, M.H. Grant, J.N.A. Tettey

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The prototype 1,4-dihydropyridine (1,4-DHP) nifedipine, indicated for the management of hypertension and angina pectoris, has drawbacks of rapid onset of vasodilating action and a short half-life. Several newer analogues have been designed to offset these problems and these include mebudipine and dibudipine. These analogues contain t-butyl substituents that have been selected to alter
the fast metabolism without altering pharmacological activity. In this study, the metabolism of mebudipine and dibudipine by isolated rat hepatocytes has been investigated. These compounds were extensively metabolized in 2 h by oxidative pathways, analogous to those known for nifedipine, and by O-glucuronidation after hydroxylation of the t-butyl substituents. The in-vitro half-lives
of mebudipine (22¯ 7.1 min) and dibudipine (40¯ 9.8 min) were significantly longer than that of nifedipine (5.5¯ 1.1 min), which was investigated in parallel in this study. These newer 1,4-DHPs address the problem of the short half-life of nifedipine and have potential for further development in view of their comparable potency to nifedipine.
LanguageEnglish
Pages1469-1475
Number of pages7
JournalJournal of Pharmacy and Pharmacology
Volume56
DOIs
Publication statusPublished - 2004

Fingerprint

Calcium Channel Blockers
Nifedipine
Hepatocytes
Half-Life
Angina Pectoris
Hydroxylation
mebudipine
1,4-dihydropyridine
dibudipine
Pharmacology
Hypertension

Keywords

  • dihydropyridine
  • calcium channel blockers
  • mebudipine
  • rat hepatocytes

Cite this

Bohlooli, S. ; Mahmoudian, M. ; Skellern, G.G. ; Grant, M.H. ; Tettey, J.N.A. / Metabolism of the novel dihydropyridine calcium channel blockers mebudipine and dibudipine by isolated rat hepatocytes. In: Journal of Pharmacy and Pharmacology. 2004 ; Vol. 56. pp. 1469-1475.
@article{6c39a2c7dcc64fd1a656562cf709b6d1,
title = "Metabolism of the novel dihydropyridine calcium channel blockers mebudipine and dibudipine by isolated rat hepatocytes",
abstract = "The prototype 1,4-dihydropyridine (1,4-DHP) nifedipine, indicated for the management of hypertension and angina pectoris, has drawbacks of rapid onset of vasodilating action and a short half-life. Several newer analogues have been designed to offset these problems and these include mebudipine and dibudipine. These analogues contain t-butyl substituents that have been selected to alterthe fast metabolism without altering pharmacological activity. In this study, the metabolism of mebudipine and dibudipine by isolated rat hepatocytes has been investigated. These compounds were extensively metabolized in 2 h by oxidative pathways, analogous to those known for nifedipine, and by O-glucuronidation after hydroxylation of the t-butyl substituents. The in-vitro half-livesof mebudipine (22¯ 7.1 min) and dibudipine (40¯ 9.8 min) were significantly longer than that of nifedipine (5.5¯ 1.1 min), which was investigated in parallel in this study. These newer 1,4-DHPs address the problem of the short half-life of nifedipine and have potential for further development in view of their comparable potency to nifedipine.",
keywords = "dihydropyridine , calcium channel blockers , mebudipine , rat hepatocytes",
author = "S. Bohlooli and M. Mahmoudian and G.G. Skellern and M.H. Grant and J.N.A. Tettey",
year = "2004",
doi = "10.1211/002235704476",
language = "English",
volume = "56",
pages = "1469--1475",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",

}

Metabolism of the novel dihydropyridine calcium channel blockers mebudipine and dibudipine by isolated rat hepatocytes. / Bohlooli, S.; Mahmoudian, M.; Skellern, G.G.; Grant, M.H.; Tettey, J.N.A.

In: Journal of Pharmacy and Pharmacology, Vol. 56, 2004, p. 1469-1475.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Metabolism of the novel dihydropyridine calcium channel blockers mebudipine and dibudipine by isolated rat hepatocytes

AU - Bohlooli, S.

AU - Mahmoudian, M.

AU - Skellern, G.G.

AU - Grant, M.H.

AU - Tettey, J.N.A.

PY - 2004

Y1 - 2004

N2 - The prototype 1,4-dihydropyridine (1,4-DHP) nifedipine, indicated for the management of hypertension and angina pectoris, has drawbacks of rapid onset of vasodilating action and a short half-life. Several newer analogues have been designed to offset these problems and these include mebudipine and dibudipine. These analogues contain t-butyl substituents that have been selected to alterthe fast metabolism without altering pharmacological activity. In this study, the metabolism of mebudipine and dibudipine by isolated rat hepatocytes has been investigated. These compounds were extensively metabolized in 2 h by oxidative pathways, analogous to those known for nifedipine, and by O-glucuronidation after hydroxylation of the t-butyl substituents. The in-vitro half-livesof mebudipine (22¯ 7.1 min) and dibudipine (40¯ 9.8 min) were significantly longer than that of nifedipine (5.5¯ 1.1 min), which was investigated in parallel in this study. These newer 1,4-DHPs address the problem of the short half-life of nifedipine and have potential for further development in view of their comparable potency to nifedipine.

AB - The prototype 1,4-dihydropyridine (1,4-DHP) nifedipine, indicated for the management of hypertension and angina pectoris, has drawbacks of rapid onset of vasodilating action and a short half-life. Several newer analogues have been designed to offset these problems and these include mebudipine and dibudipine. These analogues contain t-butyl substituents that have been selected to alterthe fast metabolism without altering pharmacological activity. In this study, the metabolism of mebudipine and dibudipine by isolated rat hepatocytes has been investigated. These compounds were extensively metabolized in 2 h by oxidative pathways, analogous to those known for nifedipine, and by O-glucuronidation after hydroxylation of the t-butyl substituents. The in-vitro half-livesof mebudipine (22¯ 7.1 min) and dibudipine (40¯ 9.8 min) were significantly longer than that of nifedipine (5.5¯ 1.1 min), which was investigated in parallel in this study. These newer 1,4-DHPs address the problem of the short half-life of nifedipine and have potential for further development in view of their comparable potency to nifedipine.

KW - dihydropyridine

KW - calcium channel blockers

KW - mebudipine

KW - rat hepatocytes

U2 - 10.1211/002235704476

DO - 10.1211/002235704476

M3 - Article

VL - 56

SP - 1469

EP - 1475

JO - Journal of Pharmacy and Pharmacology

T2 - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

ER -